Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder

Urology

Volumn 61, Issue 4, 2003, Pages 719-723

  Guan, Kao Peng ^a   Ye, Hai Yun ^a   Yan, Zheng ^a   Wang, Ying ^a   Hou, Shu Kun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOSTATIN; GELATINASE B;

ADULT; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSITIONAL CELL CARCINOMA;

EID: 0037380202     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02429-9     Document Type: Article

References (28)

1. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston clinical applications of research on angiogenesis. N Engl J Med. 333:1995;1757-1763.
2. Wossner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:1991;2145-2150.
3. Coussens L.M. Matrix metalloproteinases and the development of cancer. Chem Biol. 3:1996;895-904.
4. Kanayama H. Matrix metalloproteinases and bladder cancer. J Med Invest. 48:2001;31-43.
5. Özdemir E., Kakehi Y., Okuno H., et al. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J Urol. 161:1999;1359-1363.
6. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
7. Standker L., Schrader M., Kanse S.M., et al. Isolation and characterization of the circulating form of human endostatin. FEBS Lett. 420:1997;129-133.
8. Taddei L., Chiarugi P., Brogelli L., et al. Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem Biophys Res Commun. 263:1999;340-345.
9. Feldman A.L., Pak H., Yang J.C., et al. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer. 91:2001;1525-1529.
10. Feldman A.L., Tamarkin L., Paciotti G.F., et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV renal cancer. Clin Cancer Res. 6:2000;4628-4634.
11. Feldman A.L., Alexander H.R., Bartlett D.L., et al. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol. 8:2001;741-745.
12. Ferreras M, Felbor U, Lenhard, et al: Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 486: 247-251, 2000.
13. Felbor U., Dreier L., Bryant R.A., et al. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. 19:2000;1187-1194.
14. Wen W., Moses M.A., Wiederschain D., et al. The generation of endostatin is mediated by elastase. Cancer Res. 59:1999;6052-6056.
15. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:1990;4-6.
16. Kleiner D.E. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 43:(suppl):1999;S42-S51.
17. Bianco F.J., Gervasi D.C., Tiguert R., et al. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin Cancer Res. 4:1998;3011-3016.
18. Riedel F., Gotte K., Schwalb J., et al. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma. Anticancer Res. 20:2000;3045-3049.
19. Toshihlko I., Takehiko F., Makoto S., et al. Elevated levels of circulating matrix metalloproteinase-9 in non-small cell lung cancer patients. Clin Cancer Res. 5:1999;149-153.
20. Gerhards S., Jung F., Koenig F., et al. Excretion of matrix metalloproteinase-2 and -9 in urine is associated with a high stage and grade of bladder carcinoma. Urology. 57:2001;675-679.
21. Ramanujan S., Koenig G.C., Padera T.P., et al. Local imbalance of proangiogenic and antiangiogenic factors a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res. 60:2000;1422-1428.
22. Ding I., Sun J.Z., Fenton B., et al. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res. 61:2001;526-531.
23. Homer J.J., Greenman J., Stafford N.D., et al. Circulating angiogenic cytokines as tumor markers and prognostic factors in head and neck squamous cell carcinoma. Clin Otolaryngol. 27:2002;32-37.
24. Lai R., Estey E., Shen Y., et al. Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer. 94:2002;14-17.
25. Suzuki M., Iizasa T., Ko E., et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer. 35:2002;29-34.
26. Shaarawy M. Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer. Acta Oncol. 40:2001;513-518.
27. Kim Y.M., Jang J.W., Lee O.H., et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase 2. Cancer Res. 60:2000;5410-5413.
28. Lee S.J., Jang J.W., Kim Y.M., et al. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett. 519:2002;147-152.